LifeSci Capital initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics management to meet with Piper Sandler
- Compass Therapeutics Announces Public Offering to Raise $112.5M
- Compass Therapeutics 33.3M share Spot Secondary priced at $3.00
- Compass Therapeutics announces common stock offering, no amount given
- Compass Therapeutics price target raised to $12 from $10 at Guggenheim